Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
Uksha Saini(Ohio State University Hospital), Karuppaiyah Selvendiran(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David M. O’Malley(The Ohio State University), Ikuo Konishi(Kyoto Medical Center), G. Larry Maxwell(Inova Health System), Kalpana Deepa Priya Dorayappan(The Ohio State University Wexner Medical Center), Brentley Q. Smith(The Ohio State University Wexner Medical Center), David E. Cohn(The Ohio State University), Balveen Kaur(Augusta University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Revised FIGO staging for carcinoma of the cervix uteri
|International Journal of Gynecology & Obstetrics|2019|1k
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332